Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Endocr J ; 65(1): 113-120, 2018 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-29070763

RESUMEN

The purpose of this study is to evaluate the potential synergic effect of BRAFV600E mutation and multifocality on central lymph nodes metastasis (CLNM) in the patients with unilateral papillary thyroid carcinoma (PTC). We enrolled 413 patients with unilateral PTCs who accepted prophylactic unilateral or bilateral central lymph node dissection (LND). Univariate and multivariate analyses were made to determine the association between related factors and CLNM. Then, all patients were divided into 4 groups based on their status of BRAFV600E mutation and multifocality. Relative excess risk of interaction (RERI), attributable proportion (AP) of interaction and synergy index (SI) were applied to evaluate the interactive effect of these two factors on CLNM. Results showed that BRAFV600E mutation and multifocality were independent risk factors for CLNM. A further study revealed that unilateral PTCs accompanying multifocality with BRAFV600E mutation had the highest incidence of CLNM compared with other subgroups. Besides, RERI was 4.323 (95% CI = 1.276-7.369), AP was 0.523 (95% CI = 0.364-0.682) and SI was 2.469 (95% CI = 1.607 to 3.794), indicating a significant additive interaction of BRAFV600E mutation and multifocality on CLNM. The present study has confirmed that BRAFV600E mutation and multifocality are risk factors for CLNM in unilateral PTC. Additionally, unilateral PTC patients accompanying multifocality with BRAFV600E mutation may have an increased risk of CLNM in clinically negative CLNM.


Asunto(s)
Carcinoma Papilar/secundario , Predisposición Genética a la Enfermedad , Mutación , Proteínas Proto-Oncogénicas B-raf/genética , Neoplasias de la Tiroides/genética , Adulto , Sustitución de Aminoácidos , Instituciones Oncológicas , Carcinoma Papilar/genética , Carcinoma Papilar/metabolismo , Carcinoma Papilar/patología , Carcinoma Papilar/cirugía , China , Estudios Transversales , Análisis Mutacional de ADN , Exones , Femenino , Estudios de Asociación Genética , Humanos , Ganglios Linfáticos/metabolismo , Ganglios Linfáticos/patología , Ganglios Linfáticos/cirugía , Metástasis Linfática , Masculino , Persona de Mediana Edad , Proteínas Proto-Oncogénicas B-raf/química , Proteínas Proto-Oncogénicas B-raf/metabolismo , Estudios Retrospectivos , Cáncer Papilar Tiroideo , Glándula Tiroides/metabolismo , Glándula Tiroides/patología , Glándula Tiroides/cirugía , Neoplasias de la Tiroides/metabolismo , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/cirugía , Carga Tumoral
2.
Artículo en Chino | MEDLINE | ID: mdl-24044212

RESUMEN

OBJECTIVE: To study the effect of aluminume adjuvant and immunization schedule on immunogenicity of Sabin inactivated poliovirus vaccine. METHODS: Four batches of Sabin IPV were produced by different concentrations of type 1, 2, and 3 poliovirus and administrated on three-dose schedule at 0, 1, 2 months and 0, 2, 4 months on rats. Serum samples were collected one month after each dose and neutralizing antibody titers against three types poliovirus were determined by micro-neutralization assay. RESULTS: The GMTs of neutralizing antibodies against three types poliovirus increased significantly and the seropositivity rates were 100% in all groups after 3 doses. There was no significant difference between two immunization schedules, and the 0, 2, 4 month schedule could induce higher level neutralizing antibody compared to the 0, 1, 2 month schedule. The groups with aluminum adjuvant could induce higher level neutralizing antibody compared to the groups without adjuvant. CONCLUSION: Aluminum djuvant and immunization schedule could improve the immunogenicity of Sabin IPV.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Hidróxido de Aluminio/farmacología , Anticuerpos Antivirales/sangre , Esquemas de Inmunización , Vacuna Antipolio Oral/inmunología , Animales , Femenino , Masculino , Ratas , Ratas Wistar
3.
Med Sci Monit ; 16(8): PR9-14, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20671623

RESUMEN

BACKGROUND: There have been no studies evaluating the efficacy and potential risks of stronger neo-minophagen C (SNMC) in pregnant women with chronic hepatitis B CHB. MATERIAL/METHODS: A total of 36 pregnant women with CHB, but without severe complications, were randomized to intravenously receive SNMC or S-adenosyl-L-methionine (SAM) daily for 4 weeks or until birth. Normalization of serum alanine transaminase (ALT) and aspartate transaminase (AST) levels and changes in ALT and AST levels from baseline were determined. All neonates were regularly examined for up to 1 year. RESULTS: Treatment with SNMC and SAM resulted in normalization of ALT levels at 4 weeks in 64.3% and 21.4% of patients, respectively (OR=6.60, 95% CI: 1.23-35.44, P=0.0540). SNMC and SAM significantly decreased ALT (from 558.28+/-390.24 to 47.07+/-24.94 IU/L, P<0.0001 and from 525.61+/-483.87 to 117.43+/-85.44 IU/L, P=0.0041, respectively) and AST (from 419.72+/-409.49 to 38.14+/-18.87 IU/L, P=0.0016, and from 510.78+/-621.58 to 79.93+/-63.25 IU/L, P=0.0152, respectively) at 4 weeks relative to baseline values. Hypokalemia was observed in 4 SNMC-treated patients and in 2 SAM-treated patients and hypernatremia in 3 SNMC-treated and in 3 SAM-treated patients. Hypertension was observed in 1 SNMC-treated patient. There was no significant difference in the volume of amniotic fluid or meconium between SNMC-treated and SAM-treated groups. All the neonates were physically normal at birth and at the 1-year follow-up examination. CONCLUSIONS: Both SNMC and SAM improve liver function, with SNMC appearing more effective, in pregnant women with chronic hepatitis B without impact on fetal development.


Asunto(s)
Antivirales/administración & dosificación , Antivirales/uso terapéutico , Cisteína/administración & dosificación , Cisteína/uso terapéutico , Glicina/administración & dosificación , Glicina/uso terapéutico , Ácido Glicirretínico/análogos & derivados , Hepatitis B Crónica/tratamiento farmacológico , S-Adenosilmetionina/administración & dosificación , S-Adenosilmetionina/uso terapéutico , Adulto , Alanina Transaminasa/sangre , Antivirales/efectos adversos , Aspartato Aminotransferasas/sangre , Cisteína/efectos adversos , Cisteína/farmacología , Demografía , Combinación de Medicamentos , Quimioterapia Combinada , Desarrollo Embrionario/efectos de los fármacos , Femenino , Estudios de Seguimiento , Glicina/efectos adversos , Glicina/farmacología , Ácido Glicirretínico/administración & dosificación , Ácido Glicirretínico/efectos adversos , Ácido Glicirretínico/farmacología , Ácido Glicirretínico/uso terapéutico , Salud , Hepatitis B Crónica/sangre , Hepatitis B Crónica/fisiopatología , Humanos , Recién Nacido , Inyecciones Intravenosas , Pruebas de Función Hepática , Proyectos Piloto , Embarazo , S-Adenosilmetionina/efectos adversos , S-Adenosilmetionina/farmacología , Resultado del Tratamiento
4.
World J Gastroenterol ; 9(5): 1106-10, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12717867

RESUMEN

AIM: To determine the prevalence of nonalcoholic fatty liver in a specific population in Shanghai by an epidemiological survey, and to analyze risk factors of fatty liver. METHODS: Total 4009 administrative officers who denied regular alcohol drinking participated in the survey, and underwent physical examination and laboratory tests. The important parameters were body mass index (BMI), waist hip circumferences ratio (WHR) and levels of serum lipids. Diagnosis of fatty liver was based on established real-time ultrasonographic criteria, the presence of an ultrasonographic pattern consistent with "bright liver", with evident ultrasonographic contrast between hepatic and renal parenchyma, vessel blurring, and narrowing of the lumen of the hepatic veins. Analysis of data was performed through SPSS for Windows statistical package. RESULTS: The overall prevalence of fatty liver was 12.9 %, 15.8 % in males and 7.5 % in females, and the prevalence of fatty liver in males younger than 50 years old, was significantly higher (13.3 %) than that of in females (2.7 %). But the difference between the sexes became less significant in people older than 50 years (19.1 % vs 18.1 %). The prevalence of fatty liver was increased with age; this was markedly presented in females younger than 50 years. Multiple variant regression analysis demonstrated that the prevalence of fatty liver was positively correlated to several risk factors, including male, aging (>50yr), hyperlipidemia, impaired glucose tolerance/diabetes mellitus, hypertension and overweight/obesity. CONCLUSION: There is a high prevalence of nonalcoholic fatty liver among certain population in Shanghai, to which overweight and hyperlipidemia are closely relevant.


Asunto(s)
Hígado Graso/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Alanina Transaminasa/sangre , Glucemia/metabolismo , Constitución Corporal , Índice de Masa Corporal , China/epidemiología , Colelitiasis/complicaciones , Estudios Epidemiológicos , Hígado Graso/etiología , Femenino , Antígenos de Superficie de la Hepatitis B/sangre , Humanos , Lípidos/sangre , Masculino , Persona de Mediana Edad , Análisis Multivariante , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA